Safety and Efficacy of Antiviral Therapy of Chronic Hepatitis C in Chronic Kidney Disease and Hemodialysis Patients


  •   W. Fadili

  •   A. Ait Errami

  •   S. Zaoui

  •   K. Elkassimi

  •   N. ElBouhi

  •   S. Oubaha

  •   Z. Samlani

  •   I. Laouad

  •   K. Krati


Background and Aims: To assess the efficacy and tolerability of sofosbuvir-based antiviral therapy for viral hepatitis C (HCV) patients with chronic kidney disease and on maintenance hemodialysis.

Methods: We retrospectively reviewed all treated patients with HCV from January 2015 to November 2020. They were treated either with standard Interferon/Ribavirin or with Sofosbuvir combined to Daclatasvir or to Ledipasvir. We evaluated the sustained virologic response at 12 weeks (SVR12). Data were analyzed using SPSS 20.00.

Results: Out of 61 patients, the mean age of our patients was 56,8±12,56 years and 42,6% were males. Six patients had eGFR< 60 ml/mn/1,73 m2 (9,8%) and 26 patients were on maintenance hemodialysis (42,6%). The majority had genotype 1 and overall SVR12 was 70,1% with a rate of 75% in the Sofosbuvir-regimen subgroup. The adverse events were minor. On multivariate analysis, genotype, viral load and rapid virologic response were independent factors that significantly predicted treatment success.

Conclusion: Sofosbuvir-based regimen appears to be safe and efficious in patients with chronic kidney disease and on maintenance hemodialysis, especially in countries with limited resources.

Keywords: Chronic kidney disease, hemodialysis, hepatitis C virus, Sofosbuvir, sustained virologic response


Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection : new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013 ; 57 :1333-42.

Lee MH, Yang HI, Yuan Y, L’Italien G, Chen CJ. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol 2014; 20: 9270-80.

Daw MA, El-Bouzedi A, Ahmed MO, Dau AA, Agnan MM. Hepatitis C virus in North Africa : An emerging threat. The scientific World Journal 2016, 1-11.

Baha W, Foullous A, Dersi et al. Prevalence and risk factors of hepatitis B and C virus infections among the general population and blood donors in Morocco. BMC Public Health 2013. Vol 13, article 50.

Abdelaali BOM, Taoufik D, Samir A, Saad M. Hepatitis C viral prevalence and seroconversion in Moroccan hemodialysis units: eight year follow up. Journal of Medical Diagnostic Methods 2013. 2: 141.

Bhamidimarri KR, Czul F, Peyton A, et al. Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of hepatitis C in patients with end stage renal disease. J Hepatol 2015; 65: 763-765.

Kideny Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of hepatitis C in chronic kidney disease. Kidney International 2008; 73:S1-S99.

Goodkin DA, Bieder B, Gillespie B, Robinson BM, Jadoul M. Hepatits C infection is very rarely treated among hemodialysis patients. Am J Nephrol 2013; 38: 405-412.

Pagan J, Ladino M, Roth D. Treating hepatitis C virus in dialysis patients: How, when, and why?. Seminars in Dialysis 2018; 1-7.

Lanini S, Easterbrook PJ, Zumla A, Ippolito G. Hepatitis C: global epidemiology and strategies for control. Clin Microbiol Infect 2016; 22: 833-8.

Fabrizi F, Messa P. Treatment choices for hepatitis C in patients with kidney disease. Clin J Am Soc Nephrol 2018; 13: 793-5.

Davis MI, Chute DF, Chung RT, Sise ME. When and how can nephrologists treat hepatitis C virus infection in dialysis patients?. Seminars in Dialysis 2017; 1-11.

Ladino M, Pedraza F, Roth D. Hepatitis C virus infection in chronic kidney disease. J Am Soc Nephrol 2016; 27: 2238-2246.

Li T, Qu Y, Guo Y, Wang Y, Wang L. Efficacy and safety of direct-acting antiviral combination for patients with stage 4-5 chronic kidney disease: a meta-analysis. Liver Int 2017; 37: 974-981.

Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol 2012; 60: 2082-2089.

Shin HP, Park JA, Burman B, Kozarek RA, Siddique A. Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function. Clinical and Molecular Hepatology 2017; 23: 316-322.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3:1-150.

Koeing P, Vogel W, Umlauft F, et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kideny Int 1994;45: 1507-1509.

Fernandez J, Rendo P, Pino L. A double-blind controlled trial of recombinant interferon-α2b in hhaemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. J Viral Hepatitis. 1997;4: 113-119.

Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SUFFER study) : a combination phase 3 study. Lancet 2015; 386(10003): 1537-1545.

Henson JB, Sise ME. The association of hepatitis C infection with the onset of CKD and progression into ESRD. Seminars in Dialysis 2018;1-11.

Maruyama A, Partovi N, Yoshida EM, Erb SR, Azalgara VM, Hussaini T. A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease. Nephrol Dial Transplant 2017; 32:35-41.

Fabrizi F, Martin P, Messa P. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant. Kidney Int 2016; 89: 988-994.

Medeiros T, Rosario NF, Saraiva GN, Andrade TG, Silva AA, Almeida JR. Renal safety after one year of sofosbuvir-based therapy for chronic hepatitis C: A brazilian «real-life» study. J Clin Pharm Ther 2018;1-7.

Constancio NS, Ferraz MLG, Martins CTB, Kraychete ACK, Bitencourt PL, do Nascimento MM. Hepatitis C in hemodialysis units: diagnosis and therapeutic approach. Braz J Nephrol 2019; 41(4): 539-549.

Mandhwani R, Hanif FM, Lail G, Luck NH, Khalid MA, ul Haque MM, Laeeq SM, Aziz T. Use of sofosbuvir based regimen in patients with end-stage renal disease and chronic hepatitis C; an open label, non-randomized, single arm, single center study from Pakistan. Gastroenterol Hepatol Bed Bench 2020; 13(2): 141-146.

Saxena V, Koraishy FM, Sise ME, Lim JK, Chung RT, et al. Sfaety and efficacy if sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int 2016; 36: 807-816.

Cornprost M, Denning JM, Clemons D, Marbury TC, Alcorn H, Smith WB, et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977. J Hepatol 2012; 56: 5433.

Buti M, Riveiro-Barciela M, Esteban R. Management of direct antiviral agent failures. J Hepatol 2015; 63: 1511-1552.


Download data is not yet available.


How to Cite
Fadili, W., Ait Errami, A., Zaoui, S., Elkassimi, K., ElBouhi, N., Oubaha, S., Samlani, Z., Laouad, I., & Krati, K. (2021). Safety and Efficacy of Antiviral Therapy of Chronic Hepatitis C in Chronic Kidney Disease and Hemodialysis Patients. European Journal of Medical and Health Sciences, 3(1), 160-164.